All In Biotech

Drug Trial Radar · NCT04787744

Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for OligoRecurrenT Prostate Cancer (VA STARPORT)

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 378 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

378

Actual

Start

Jul 1, 2021

Primary completion

Oct 2, 2026

Study completion Mar 30, 2029

Sponsor

Lead sponsor
VA Office of Research and DevelopmentFederal agency
Sponsor type
Federal agency
First posted
Mar 9, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival (CRPC-free survival) for Veterans with oligometastatic prostate cancer. Oligometastasis will be defined as 1-10 sites of metastatic disease based on the clinical determination of the LSI which incorporates all imaging, clinical, and pathologic data available.

Conditions

  • Prostate Cancer
  • Oligometastasis
  • Oligorecurrence
  • Recurrent Prostate Cancer
  • Metastatic Prostate Cancer
  • De Novo Prostate Cancer

Interventions

  • PET-directed Local Therapy using SurgeryProcedure

    Surgery will be used to treat metastases.

  • PET-directed Local Therapy using RadiationRadiation

    Radiation therapy will be used to treat metastases. Radiation options include: 1. Stereotactic body radiotherapy (SBRT) using 1-10 fractions 2. Conventionally fractionated radiotherapy using elective nodal radiotherapy and a simultaneous integrated boost to involved nodes The selection of the form of metastasis-directed radiotherapy for each metastasis will be determined using shared decision-making between the treating physician and the Veteran.

  • Salvage Local Therapy for locally recurrent diseaseOther

    For Veterans who have a local recurrence in addition to oligorecurrent metastatic lesions, they will undergo salvage local therapy using brachytherapy, SBRT, surgery, cryotherapy or HIFU. The selection of modality of salvage local therapy will be determined using shared decision-making between the treating physician and Veteran.

  • Goserelin, Histrelin, Leuprolide & TriptorelinDrug

    Androgen deprivation therapy (ADT) using an LHRH agonist

  • ADT + Nilutamide, Flutamide, & BicalutamideDrug

    ADT adding anti-androgen therapy to an LHRH agonist

  • Degarelix & RelugolixDrug

    ADT using an LHRH Antagonist.

  • ADT + Docetaxel +/- prednisoneDrug

    Enhanced SST using chemohormonal therapy

  • ADT + Abiraterone + PrednisoneDrug

    Enhanced SST using Abiraterone + Prednisone

  • ADT + Abiraterone + MethylprednisoloneDrug

    Enhanced SST using Abiraterone + Methylprednisolone

  • ADT + ApalutamideDrug

    Enhanced SST using ADT + Apalutamide

  • ADT + EnzalutamideDrug

    Enhanced SST using ADT + Enzalutamide

  • Prostate-directed Radiation for De novo oligometastatic prostate cancerRadiation

    Veterans in ARM 1 will receive prostate-directed RT only and NO treatment to any nodal or distant metastatic sites. Acceptable dose/fractionations include 55 Gy in 20 fractions and 36 Gy in 6 fractions. Veterans in ARM 2 should receive prostate-directed local therapy using radiotherapy or radical prostatectomy in addition to PET-directed local therapy to metastases.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Castration-resistant prostate cancer-free survival (CRPC-free survival)Time frame: 4 years

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • VA Long Beach Healthcare System, Long Beach, CA

    Long Beach, California

  • VA Greater Los Angeles Healthcare System, West Los Angeles, CA

    West Los Angeles, California

  • Washington DC VA Medical Center, Washington, DC

    Washington D.C., District of Columbia

  • Bay Pines VA Healthcare System, Pay Pines, FL

    Bay Pines, Florida

  • Edward Hines Jr. VA Hospital, Hines, IL

    Hines, Illinois

  • Richard L. Roudebush VA Medical Center, Indianapolis, IN

    Indianapolis, Indiana

  • Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD

    Baltimore, Maryland

  • VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA

    Boston, Massachusetts

  • VA Ann Arbor Healthcare System, Ann Arbor, MI

    Ann Arbor, Michigan

  • Minneapolis VA Health Care System, Minneapolis, MN

    Minneapolis, Minnesota

  • Kansas City VA Medical Center, Kansas City, MO

    Kansas City, Missouri

  • East Orange Campus of the VA New Jersey Health Care System, East Orange, NJ

    East Orange, New Jersey

  • VA NY Harbor Healthcare System, New York, NY

    New York, New York

  • Durham VA Medical Center, Durham, NC

    Durham, North Carolina

  • Louis Stokes VA Medical Center, Cleveland, OH

    Cleveland, Ohio

  • Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA

    Philadelphia, Pennsylvania

  • Michael E. DeBakey VA Medical Center, Houston, TX

    Houston, Texas

  • Hunter Holmes McGuire VA Medical Center, Richmond, VA

    Richmond, Virginia

  • William S. Middleton Memorial Veterans Hospital, Madison, WI

    Madison, Wisconsin

  • Clement J. Zablocki VA Medical Center, Milwaukee, WI

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.